BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Innovent Biologics and Roche Forge Strategic Alliance to Advance DLL3-Targeted ADC for Small Cell Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

January 02, 2025 | News

Sensorion Completes Enrollment for First Cohort in Audiogene Phase 1/2 Gene Therapy Trial

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to re...

January 01, 2025 | News

CARsgen Launches Clinical Trial in China for Innovative Allogeneic CAR T Therapy Targeting CD19/CD20

CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...

January 01, 2025 | News

Radiopharm and Lantheus Join Forces to Advance Radiopharmaceutical Clinical Development in Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging t...

December 31, 2024 | News

CARsgen's Satricabtagene Autoleucel Achieves Positive Phase II Results in Advanced Gastric Cancer

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic mal...

December 31, 2024 | News

Alphamab Oncology Gains Approval for Phase III Clinical Study of Anti-HER2 ADC JSKN003 in Platinum-Resistant Ovarian Cancer

Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for...

December 30, 2024 | News

Exicure Signs MOU to Acquire GPCR USA and Advance Collaborative Research in Drug Development

Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...

December 30, 2024 | News

Microtech Launches Clinical Trials for Pioneering Microsensor Platform in Heart Failure Treatment

Microtech, a wholly owned subsidiary of Medinol Inc., a leader in global MedTech research and development, announced that it has initiated human clinical t...

December 27, 2024 | News

Alphamab Oncology Receives NMPA Approval for Phase I/II Trial of Groundbreaking Subcutaneous Co-Formulation JSKN033

Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co...

December 27, 2024 | News

Jadeite Medicines Transfers NDA for Odevixibat in PFIC to Ipsen for Commercialization in Japan

Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered in Tokyo, Japan (President & CEO, Eiichi Takahashi...

December 26, 2024 | News

Ractigen Therapeutics Doses First Patient in Phase I Trial of RAG-17 for SOD1-Linked ALS

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosin...

December 25, 2024 | News

Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in NSCLC

Daiichi Sankyo and AstraZeneca have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DX...

December 25, 2024 | News

Keymed Biosciences Secures NMPA Approval for Stapokibart to Treat Chronic Rhinosinusitis with Nasal Polyposis

Keymed Biosciences Inc. announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New D...

December 24, 2024 | News

Ellipses Pharma Launches Middle East’s First Large-Scale Oncology Phase 1/2 Clinical Study

Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an...

December 23, 2024 | News

Stay Connected